New drug aims to help kidney patients breathe easier and move better

NCT ID NCT07355062

Recruiting now Disease control Sponsor: Renibus Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an investigational drug called veverimer can safely help adults with moderate-to-severe chronic kidney disease (CKD) who also have metabolic acidosis, a condition where too much acid builds up in the blood. Over 26 weeks, researchers will measure if the drug improves blood chemistry, physical strength, walking ability, and quality of life. The goal is to see if this treatment can better manage the complications of kidney disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Academic Medical Research Institute
RECRUITING

Los Angeles, California, 90022, United States
Belkis Delgado MD PA
RECRUITING

Miami Springs, Florida, 33166, United States
Brookview Hills Research Associates
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Clinical Advancement Center
RECRUITING

San Antonio, Texas, 78212, United States
Nephrology Associates of Kentuckiana
RECRUITING

Louisville, Kentucky, 40205, United States
New York-Presbyterian Queens
RECRUITING

Fresh Meadows, New York, 11365, United States
Research by Design
RECRUITING

Chicago, Illinois, 60643, United States
Velocity Clinical Research
RECRUITING

Edgewater, Florida, 32132, United States

Conditions

Explore the condition pages connected to this study.

CKD METABOLIC ACIDOSIS